The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Systemic treatment preferences for patients with advanced desmoid-type fibromatosis (DF) in Europe.
 
Thomas Van Cann
Travel, Accommodations, Expenses - PharmaMar
 
Annelies Requilé
No Relationships to Disclose
 
Patrick Schoffski
Honoraria - Daiichi Sankyo; Eisai; Lilly; Medpace; Novartis; Swedish Orphan Biovitrum
Consulting or Advisory Role - 6th Element Capital (Inst); Adaptimmune (Inst); Amcure (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cristal Therapeutics (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Epizyme (Inst); Genzyme (Inst); Ipsen (Inst); Lilly (Inst); Loxo (Inst); Medpace (Inst); Nektar (Inst); Novartis (Inst); Philogen (Inst); Pique (Inst); Plexxikon (Inst)
Speakers' Bureau - Bayer; Eisai; GlaxoSmithKline; Lilly; Novartis; PharmaMar; Swedish Orphan Biovitrum
Research Funding - Bayer (Inst); Blueprint Medicines (Inst); CoBioRes NV (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - 6th element Capital; Adaptimmune; Amcure; AstraZeneca; Bayer; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Cristal Therapeutics; Daiichi Sankyo; Eisai; Epizyme; Genzyme; GlaxoSmithKline; Ipsen; Lilly; Loxo; Medpace; Nektar; Novartis; PharmaMar; Philogen; Pique; Plexxikon; Swedish Orphan Biovitrum